[1]
R. Ravasio, S. Antonelli, A. Maiorino, A. Costanzo, and S. Losi, “Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy”, Grhta, vol. 6, no. 1, Jan. 2019.